Virtual screen to NMR (VS2NMR): Discovery of fragment hits for the CBP bromodomain

被引:17
|
作者
Spiliotopoulos, Dimitrios [1 ]
Zhu, Jian [1 ]
Wamhoff, Eike-Christian [2 ,3 ]
Deerain, Nicholas [1 ]
Marchand, Jean-Remy [1 ]
Aretz, Jonas [2 ,3 ]
Rademacher, Christoph [2 ,3 ]
Caflisch, Amedeo [1 ]
机构
[1] Univ Zurich, Dept Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland
[2] Max Planck Inst Colloids & Interfaces, Dept Biomol Syst, Muhlenberg 1, D-14424 Potsdam, Germany
[3] Free Univ Berlin, Dept Biol Chem & Pharm, Inst Med & Biochem, Takustr 3, D-14195 Berlin, Germany
基金
瑞士国家科学基金会;
关键词
Docking; Virtual screening; NMR spectroscopy; Epigenetics; X-ray crystallography; Bromodomain inhibitors; BINDING; INHIBITORS; LIGANDS; DOCKING; POTENT; BRD4; IDENTIFICATION; OPTIMIZATION; DESIGN;
D O I
10.1016/j.bmcl.2017.04.001
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Overexpression of the CREB-binding protein (CBP), a bromodomain-containing transcription coactivator involved in a variety of cellular processes, has been observed in several types of cancer with a correlation to aggressiveness. We have screened a library of nearly 1500 fragments by high-throughput docking into the CBP bromodomain followed by binding energy evaluation using a force field with electrostatic solvation. Twenty of the 39 fragments selected by virtual screening are positive in one or more ligand-observed nuclear magnetic resonance (NMR) experiments. Four crystal structures of the CBP bromodomain in complex with in silico screening hits validate the pose predicted by docking. Thus, the success ratio of the high-throughput docking procedure is 50% or 10% if one considers the validation by ligand-observed NMR spectroscopy or X-ray crystallography, respectively. Compounds 1 and 3 show favorable ligand efficiency in two different in vitro binding assays. The structure of the CBP bromodomain in the complex with the brominated pyrrole 1 suggests fragment growing by Suzuki coupling. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2472 / 2478
页数:7
相关论文
共 50 条
  • [1] NMR methods in fragment based drug discovery
    Lim, Jongsoo
    JOURNAL OF THE KOREAN MAGNETIC RESONANCE SOCIETY, 2015, 19 (03): : 132 - 136
  • [2] NMR characterization of weak interactions between RhoGDI2 and fragment screening hits
    Liu, Jiuyang
    Gao, Jia
    Li, Fudong
    Ma, Rongsheng
    Wei, Qingtao
    Wang, Aidong
    Wu, Jihui
    Ruan, Ke
    BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2017, 1861 (01): : 3061 - 3070
  • [3] Practical aspects of NMR-based fragment discovery
    Zartler, Edward R.
    Mo, Huaping
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2007, 7 (16) : 1592 - 1599
  • [4] NMR Screening in the Fragment-based Drug Discovery
    Hanzawa, Hiroyuki
    Takizawa, Takeshi
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2010, 130 (03): : 325 - 333
  • [5] NMR Screening and Hit Validation in Fragment Based Drug Discovery
    Campos-Olivas, Ramon
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2011, 11 (01) : 43 - 67
  • [6] Fragment-based drug discovery using NMR spectroscopy
    Harner, Mary J.
    Frank, Andreas O.
    Fesik, Stephen W.
    JOURNAL OF BIOMOLECULAR NMR, 2013, 56 (02) : 65 - 75
  • [7] Fragment-based drug discovery using NMR spectroscopy
    Mary J. Harner
    Andreas O. Frank
    Stephen W. Fesik
    Journal of Biomolecular NMR, 2013, 56 : 65 - 75
  • [8] NMR-Fragment Based Virtual Screening: A Brief Overview
    Singh, Meenakshi
    Tam, Benjamin
    Akabayov, Barak
    MOLECULES, 2018, 23 (02):
  • [9] Metabolite profiling by NMR for high-throughput mode of action identification of screen hits
    Hadfield, ST
    Hole, SJW
    Howe, PWA
    Stanley, PD
    BCPC CONFERENCE - WEEDS 2001, VOLS 1 AND 2, 2001, : 551 - 556
  • [10] Crystallography, NMR and virtual screening: Integrated tools for drug discovery
    Muchmore, SW
    Hajduk, PJ
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2003, 6 (04) : 544 - 549